Terms: = Sarcomas AND PDGFRA, MGC74795, 5156, ENSG00000134853, PDGFR2, CD140A, Rhe-PDGFRA, CD140a, P16234
302 results:
1. KIT/pdgfra inhibitors for the treatment of gastrointestinal stromal tumors: getting to the gist of the problem.
Cicala CM; Olivares-Rivas I; Aguirre-Carrillo JA; Serrano C
Expert Opin Investig Drugs; 2024 Mar; 33(3):159-170. PubMed ID: 38344849
[TBL] [Abstract] [Full Text] [Related]
2. Avapritinib-based SAR studies unveil a binding pocket in KIT and pdgfra.
Teuber A; Schulz T; Fletcher BS; Gontla R; Mühlenberg T; Zischinsky ML; Niggenaber J; Weisner J; Kleinbölting SB; Lategahn J; Sievers S; Müller MP; Bauer S; Rauh D
Nat Commun; 2024 Jan; 15(1):63. PubMed ID: 38167404
[TBL] [Abstract] [Full Text] [Related]
3. Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007-001 Studies.
Heinrich MC; Zhang X; Jones RL; George S; Serrano C; Deng Y; Bauer S; Cai S; Wu X; Zhou Y; Tao K; Zheng Z; Zhang J; Cui Y; Cao H; Wang M; Hu J; Yang J; Li J; Shen L
Clin Cancer Res; 2024 Feb; 30(4):719-728. PubMed ID: 38032349
[TBL] [Abstract] [Full Text] [Related]
4. Receptor tyrosine kinase gene expression profiling of orbital rhabdomyosarcoma unveils MET as a potential biomarker and therapeutic target.
Chauhan S; Sen S; Irshad K; Kashyap S; Pushker N; Meel R; Sharma MC
Hum Cell; 2024 Jan; 37(1):297-309. PubMed ID: 37914903
[TBL] [Abstract] [Full Text] [Related]
5. Morphological, immunohistochemical, and genetic analyses of epithelioid gastrointestinal stromal tumors.
Shi J; Sun K; Kong F; Shen D
Ann Diagn Pathol; 2023 Dec; 67():152208. PubMed ID: 37696133
[TBL] [Abstract] [Full Text] [Related]
6. Single-cell RNA sequencing of human non-hematopoietic bone marrow cells reveals a unique set of inter-species conserved biomarkers for native mesenchymal stromal cells.
Fiévet L; Espagnolle N; Gerovska D; Bernard D; Syrykh C; Laurent C; Layrolle P; De Lima J; Justo A; Reina N; Casteilla L; Araúzo-Bravo MJ; Naji A; Pagès JC; Deschaseaux F
Stem Cell Res Ther; 2023 Aug; 14(1):229. PubMed ID: 37649081
[TBL] [Abstract] [Full Text] [Related]
7. Sarcoma care in the era of precision medicine.
Wallander K; Öfverholm I; Boye K; Tsagkozis P; Papakonstantinou A; Lin Y; Haglund de Flon F
J Intern Med; 2023 Dec; 294(6):690-707. PubMed ID: 37643281
[TBL] [Abstract] [Full Text] [Related]
8. REGISTRI: Regorafenib in first-line of KIT/pdgfra wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial.
Martin-Broto J; Valverde C; Hindi N; Vincenzi B; Martinez-Trufero J; Grignani G; Italiano A; Lavernia J; Vallejo A; Tos PD; Le Loarer F; Gonzalez-Campora R; Ramos R; Hernández-Jover D; Gutierrez A; Serrano C; Monteagudo M; Letón R; Robledo M; Moura DS; Martin-Ruiz M; López-Guerrero JA; Cruz J; Fernandez-Serra A; Blay JY; Fumagalli E; Martinez-Marin V
Mol Cancer; 2023 Aug; 22(1):127. PubMed ID: 37559050
[TBL] [Abstract] [Full Text] [Related]
9. Clinicopathological and molecular analyses of uterine carcinosarcomas using next-generation sequencing: A single-center experience.
Erdogan EG; Yalta TD; Can N; Süt N; Taştekin E; Usta U; Puyan FÖ; Usturalı Keskin FE; Kurt BB
Indian J Pathol Microbiol; 2023; 66(3):449-455. PubMed ID: 37530323
[TBL] [Abstract] [Full Text] [Related]
10. Multiple intratumoral sources of kit ligand promote gastrointestinal stromal tumor.
Tieniber AD; Rossi F; Hanna AN; Liu M; Etherington MS; Loo JK; Param N; Zeng S; Do K; Wang L; DeMatteo RP
Oncogene; 2023 Aug; 42(34):2578-2588. PubMed ID: 37468679
[TBL] [Abstract] [Full Text] [Related]
11. A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor.
George S; Heinrich MC; Somaiah N; Oppelt P; McLeod R; Nishioka S; Kundu MG; Qian X; Kumar P; Laadem A; Lau Y; Tran BP; Fallon M; Dosunmu O; Shi J; Naito Y
Clin Cancer Res; 2023 Sep; 29(18):3659-3667. PubMed ID: 37363962
[TBL] [Abstract] [Full Text] [Related]
12. Molecular Advances in the Treatment of Advanced Gastrointestinal Stromal Tumor.
Venkataraman V; George S; Cote GM
Oncologist; 2023 Aug; 28(8):671-681. PubMed ID: 37315115
[TBL] [Abstract] [Full Text] [Related]
13. The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): A lesson from ripretinib.
Di Vito A; Ravegnini G; Gorini F; Aasen T; Serrano C; Benuzzi E; Coschina E; Monesmith S; Morroni F; Angelini S; Hrelia P
Pharmacol Ther; 2023 Aug; 248():108475. PubMed ID: 37302758
[TBL] [Abstract] [Full Text] [Related]
14. SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022).
Serrano C; Álvarez R; Carrasco JA; Marquina G; Martínez-García J; Martínez-Marín V; Sala MÁ; Sebio A; Sevilla I; Martín-Broto J
Clin Transl Oncol; 2023 Sep; 25(9):2707-2717. PubMed ID: 37129716
[TBL] [Abstract] [Full Text] [Related]
15. Surgical Management of Germline Gastrointestinal Stromal Tumor.
Kwak HV; Tardy KJ; Allbee A; Stashek K; DeMatteo RP
Ann Surg Oncol; 2023 Aug; 30(8):4966-4974. PubMed ID: 37115371
[TBL] [Abstract] [Full Text] [Related]
16. Intimal Sarcoma with MDM2/CDK4 Amplification and p16 Overexpression: A Review of Histological Features in Primary Tumor and Xenograft, with Immunophenotype and Molecular Profiling.
Giner F; Machado I; Rubio-Martínez LA; López-Guerrero JA; Claramunt-Alonso R; Navarro S; Ferrández A; Mayordomo-Aranda E; Llombart-Bosch A
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108696
[TBL] [Abstract] [Full Text] [Related]
17. LIX1 Controls MAPK Signaling Reactivation and Contributes to GIST-T1 Cell Resistance to Imatinib.
Ruiz-Demoulin S; Trenquier E; Dekkar S; Deshayes S; Boisguérin P; Serrano C; de Santa Barbara P; Faure S
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108337
[TBL] [Abstract] [Full Text] [Related]
18. Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib.
Serrano C; Bauer S; Gómez-Peregrina D; Kang YK; Jones RL; Rutkowski P; Mir O; Heinrich MC; Tap WD; Newberry K; Grassian A; Shi H; Bialick S; Schöffski P; Pantaleo MA; von Mehren M; Trent JC; George S
Ann Oncol; 2023 Jul; 34(7):615-625. PubMed ID: 37105265
[TBL] [Abstract] [Full Text] [Related]
19. KIT and pdgfra Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial.
Joensuu H; Wardelmann E; Eriksson M; Reichardt A; Hall KS; Schütte J; Cameron S; Hohenberger P; Sihto H; Jost PJ; Lindner LH; Bauer S; Nilsson B; Kallio R; Pesonen T; Reichardt P
Clin Cancer Res; 2023 Sep; 29(17):3313-3319. PubMed ID: 37014660
[TBL] [Abstract] [Full Text] [Related]
20. Co-targeting of ACK1 and KIT triggers additive anti-proliferative and -migration effects in imatinib-resistant gastrointestinal stromal tumors.
He W; Xu L; Ding J; Song L; Yang W; Klooster I; Pilco-Janeta DF; Serrano C; Fang H; Jiang G; Wang X; Yu J; Ou WB
Biochim Biophys Acta Mol Basis Dis; 2023 Jun; 1869(5):166690. PubMed ID: 36921738
[TBL] [Abstract] [Full Text] [Related]
[Next]
